IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
Open Access
- 16 October 2001
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 85 (8), 1130-1136
- https://doi.org/10.1054/bjoc.2001.2076
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II studyBritish Journal of Cancer, 2000
- Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.1990
- Cardiorespiratory effects of immunotherapy with interleukin-2.Journal of Clinical Oncology, 1989
- Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.The Journal of Immunology, 1986
- Prognostic Factors in Metastatic Renal CarcinomaJournal of Urology, 1986
- Therapeutic options in renal-cell carcinoma.1985
- Renal Cell Carcinoma: Natural History and Results of TreatmentJournal of Urology, 1978